<DOC>
	<DOC>NCT00867087</DOC>
	<brief_summary>The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>CD20/CD22positive diffuse large Bcell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy Relapsed/disease progression within 12 months after start of prior therapy and/or secondary International Prognostic Index (sIPI) score greater than 1 Eligible for autologous stem cell transplant (aSCT) Prior allogeneic hematopoietic stem cell transplant Within 6 months prior to test article: autologous transplant, treatment with antiCD22 antibodies, radioimmunotherapy Venoocclusive disease or sinusoidal obstruction syndrome, chronic liver disease, systemic vasculitides, current or chronic hepatitis B or C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Diffuse large b-cell lymphoma</keyword>
	<keyword>inotuzumab ozogamicin</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>